- Home
- ODYS vs LPTX Comparison
ODYS vs LPTX Comparison
Compare ODYS & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ODYS
- LPTX
- Stock Information
- Founded
- ODYS N/A
- LPTX 2011
- Country
- ODYS Israel
- LPTX United States
- Employees
- ODYS N/A
- LPTX N/A
- Industry
- ODYS
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ODYS
- LPTX Health Care
- Exchange
- ODYS NYSE
- LPTX Nasdaq
- Market Cap
- ODYS 107.4M
- LPTX 119.6M
- IPO Year
- ODYS N/A
- LPTX N/A
- Fundamental
- Price
- ODYS $6.66
- LPTX $0.29
- Analyst Decision
- ODYS
- LPTX Buy
- Analyst Count
- ODYS 0
- LPTX 2
- Target Price
- ODYS N/A
- LPTX $8.00
- AVG Volume (30 Days)
- ODYS 20.5K
- LPTX 5.8M
- Earning Date
- ODYS 03-28-2025
- LPTX 03-26-2025
- Dividend Yield
- ODYS N/A
- LPTX N/A
- EPS Growth
- ODYS N/A
- LPTX N/A
- EPS
- ODYS N/A
- LPTX N/A
- Revenue
- ODYS $3,964,000.00
- LPTX N/A
- Revenue This Year
- ODYS N/A
- LPTX N/A
- Revenue Next Year
- ODYS N/A
- LPTX N/A
- P/E Ratio
- ODYS N/A
- LPTX N/A
- Revenue Growth
- ODYS 30.70
- LPTX N/A
- 52 Week Low
- ODYS $5.01
- LPTX $0.28
- 52 Week High
- ODYS $10.80
- LPTX $4.79
- Technical
- Relative Strength Index (RSI)
- ODYS N/A
- LPTX 25.26
- Support Level
- ODYS N/A
- LPTX $0.28
- Resistance Level
- ODYS N/A
- LPTX $0.65
- Average True Range (ATR)
- ODYS 0.00
- LPTX 0.05
- MACD
- ODYS 0.00
- LPTX 0.02
- Stochastic Oscillator
- ODYS 0.00
- LPTX 5.35
About ODYS ODYSIGHT AI INC
Odysight ai Inc is engaged in the development, production, and marketing of innovative Predictive Maintenance (PdM) and Condition Based Monitoring (CBM) technologies, providing visual sensing and AI-based video analytics solutions for critical systems in the aviation, maritime, industrial non-destructing-testing industries, transportation, and energy industries.
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .